Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tert-Butanol SCHEMBL20985481 | 0.97 | ALDH1A1 (0.69) | ALDH1A1SMN1; SMN2TSHRLMNAMEN1 | |
| Tert-Butanol SCHEMBL5623893 | 0.97 | ALDH1A1 (0.69) | ALDH1A1SMN1; SMN2TSHRLMNAMEN1 | |
| 1-Pentanol SCHEMBL2001508 | 0.90 | SMN1; SMN2 (0.75) | ALDH1A1SMN1; SMN2TSHRLMNAMEN1 | |
| 1-Hexanol SCHEMBL10954739 | 0.88 | LMNA (0.77) | ALDH1A1SMN1; SMN2TSHRLMNAMEN1 | |
| Amylene Hydrate SCHEMBL7787345 | 0.88 | ALDH1A1 (0.65) | ALDH1A1SMN1; SMN2TSHRLMNAMEN1 | |
| Octanol SCHEMBL28470883 | 0.88 | LMNA (0.77) | ALDH1A1SMN1; SMN2TSHRLMNAMEN1 | |
| Butyl Alcohol SCHEMBL9725477 | 0.86 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2TSHRLMNAMEN1 | |
| Butyl Alcohol SCHEMBL532 | 0.86 | — | — | |
| Butyl Alcohol SCHEMBL30877879 | 0.86 | — | — | |
| Butyl Alcohol SCHEMBL29688432 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101891179-A | Preparation method of lithium iron phosphate material, lithium ion battery and positive plate thereof | WANXING PHOTOELECTRON DONGGUAN CO LTD | 2010-11-24 | — | — | CN | claimed |
| WO-2010095024-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF CELECOXIB | AUROBINDO PHARMA LIMITED (IN) | 2010-08-26 | — | — | WO | claimed |
| CN-1233689-C | Double metal complex catalyst and its prepn | LIMING CHEMICAL INST (CN) | 2005-12-28 | — | — | CN | claimed |
| CN-1486788-A | Double metal complex catalyst and its prepn | 黎明化工研究院 | 2004-04-07 | — | — | CN | claimed |
| CN-113387954-B | Preparation method of adefovir intermediate | 上海特化医药科技有限公司 | 2024-03-19 | — | — | CN | disclosed |
| EP-4253366-A2 | METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION | Gilead Sciences, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| CN-111057052-B | Method for preparing minodronic acid intermediate 2- (imidazo [1, 2-alpha ] pyridine-3-yl) acetate compound | 复旦大学 | 2023-08-22 | — | — | CN | disclosed |
| EP-3752496-B1 | METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION | GILEAD SCIENCES INC (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-115557533-A | Recycling method of arsenic sulfide slag | 林西金易来砷业有限公司 | 2023-01-03 | — | — | CN | disclosed |
| CN-111057052-A | Method for preparing minodronic acid intermediate 2- (imidazo [1,2- α ] pyridine-3-yl) acetic ester compound | 复旦大学 | 2020-04-24 | — | — | CN | disclosed |
| CN-106265500-B | Solution containing miboplatin, application of solution, miboplatin freeze-dried powder injection, preparation method and application | 袁利佳 | 2020-01-31 | — | — | CN | disclosed |
| CN-106117083-A | Method for producing 2-cyanoethyl-5-norbornene-2-aldehyde in a microstructured reactor | 南京工业大学 | 2016-11-16 | — | — | CN | disclosed |
| US-20060014798-A1 | Process for the preparation of sulphinyl derivatives by oxidation of the corresponding sulfides | CHEMI SPA (IT) | 2006-01-19 | — | — | US | disclosed |
| CN-1233689-C | Double metal complex catalyst and its prepn | LIMING CHEMICAL INST (CN) | 2005-12-28 | — | — | CN | disclosed |
| CN-1486788-A | Double metal complex catalyst and its prepn | 黎明化工研究院 | 2004-04-07 | — | — | CN | disclosed |
| CN-1486788-A | Double metal complex catalyst and its prepn | 黎明化工研究院 | 2004-04-07 | — | — | CN | disclosed |
| US-6593364-B2 | Oxireno-, azetidino-, and methano- picene derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-07-15 | — | — | US | disclosed |
| US-20020016481-A1 | Triterpene derivatives and remedies for liver diseases | SASAKI KAZUE (JP) | 2002-02-07 | — | — | US | disclosed |
| EP-1087005-A1 | Fluorescent diketopyrrolopyrroles | Ciba SC Holding AG (CH) | 2001-03-28 | — | — | EP | disclosed |
| US-4145420-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1979-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016481-A1 | Triterpene derivatives and remedies for liver diseases | NR1H3, NR1H2, OXER1 | ALDH1A1 803/4885SMN1; SMN2 4624/4885TSHR 940/4885 |
| US-20060014798-A1 | Process for the preparation of sulphinyl derivatives by oxidation of the corresponding sulfides | SQOR, STS, SI | ALDH1A1 1094/4885SMN1; SMN2 2795/4885TSHR 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.